Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
Dicer and microRNA-155 dysregulation in multiple sclerosis: biomarkers for disease progression and treatment response.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Madany Nadia M H, El-Seidi Mona I A, Mourad Husam S, Abdelmaseeh Mona A, Mowafy Hagar L
Аннотация
BACKGROUND: Multiple Sclerosis (MS) is an immunological disorder that progressively leads to neurological dysfunction. Dysregulated microRNA expression, particularly miR-155, has been implicated in MS pathogenesis. Dicer, an enzyme responsible for processing precursor microRNAs into their mature forms, is also dysregulated in various conditions, including MS.
OBJECTIVES: This study aimed to assess plasma expression levels of miR-155 and Dicer mRNA in MS patients compared to healthy individuals and evaluate their diagnostic value and clinical significance.
METHODS: We analyzed plasma samples from twenty untreated MS patients, 20 MS patients receiving IFNβ1a therapy, and twenty healthy controls. Quantitative real-time PCR was used to quantify miR-155 and Dicer mRNA levels.
RESULTS: MiR-155 was significantly higher in untreated MS patients compared to both healthy controls and IFNβ1a-treated group (p < 0.001). MiR-155 correlated positively with the Expanded Disability Status Scale (EDSS) (r = 0.683, p < 0.001). Conversely, plasma Dicer mRNA levels didn't differ significantly between untreated MS patients and controls. However, Dicer mRNA expression was significantly elevated in the IFNβ1a-treated patients compared to both untreated MS patients (p < 0.001) and healthy controls (p = 0.001).
CONCLUSIONS: Our findings suggest that miR-155 may serve as a promising biomarker for MS diagnosis and disease severity. While Dicer mRNA expression showed limited diagnostic utility, its upregulation in IFNβ1a-treated patients suggests a potential role in monitoring disease progression and treatment response.
OBJECTIVES: This study aimed to assess plasma expression levels of miR-155 and Dicer mRNA in MS patients compared to healthy individuals and evaluate their diagnostic value and clinical significance.
METHODS: We analyzed plasma samples from twenty untreated MS patients, 20 MS patients receiving IFNβ1a therapy, and twenty healthy controls. Quantitative real-time PCR was used to quantify miR-155 and Dicer mRNA levels.
RESULTS: MiR-155 was significantly higher in untreated MS patients compared to both healthy controls and IFNβ1a-treated group (p < 0.001). MiR-155 correlated positively with the Expanded Disability Status Scale (EDSS) (r = 0.683, p < 0.001). Conversely, plasma Dicer mRNA levels didn't differ significantly between untreated MS patients and controls. However, Dicer mRNA expression was significantly elevated in the IFNβ1a-treated patients compared to both untreated MS patients (p < 0.001) and healthy controls (p = 0.001).
CONCLUSIONS: Our findings suggest that miR-155 may serve as a promising biomarker for MS diagnosis and disease severity. While Dicer mRNA expression showed limited diagnostic utility, its upregulation in IFNβ1a-treated patients suggests a potential role in monitoring disease progression and treatment response.